November 19, 2025
Back to all stories

Mifepristone lawsuits update; new FOIA case

Amid ongoing litigation over mifepristone, HHS Secretary Robert F. Kennedy Jr. ordered a new FDA safety review citing a self‑published white paper funded and publicized by anti‑abortion groups, including Americans United for Life, which criticized the FDA’s approval of a new generic. Alliance Defending Freedom says it represents a Louisiana plaintiff in related litigation and expects an appeal of a recent court order, while the ACLU’s Nov. 13 FOIA suit seeks the parameters of the FDA review and the agency’s communications with outside groups.

Legal Health

📌 Key Facts

  • HHS Secretary Robert F. Kennedy Jr. ordered a new FDA review of mifepristone’s safety, citing a self‑published white paper funded by anti‑abortion groups as the basis for the review.
  • Americans United for Life and allied anti‑abortion groups criticized the FDA’s approval of a new generic mifepristone and helped produce and publicize the white paper that prompted the review.
  • Alliance Defending Freedom says it represents a Louisiana plaintiff in a medication‑abortion lawsuit against the FDA and expects the administration to appeal a recent court order in that case.
  • The ACLU filed a FOIA lawsuit on Nov. 13 seeking the parameters of the FDA’s new mifepristone review and the agency’s communications with outside groups about that review.
  • Together, the ordered FDA review, litigation from anti‑abortion groups, and the ACLU FOIA suit indicate escalating legal and public scrutiny over mifepristone’s approval and the FDA’s handling of its safety review.

📰 Sources (2)

Mifepristone on trial: Where lawsuits about a key abortion medication stand
Minnesota Reformer by Sofia Resnick November 19, 2025
FDA’s abortion-pill safety review under growing scrutiny
Minnesota Reformer by Sofia Resnick November 19, 2025
New information:
  • HHS Secretary Robert F. Kennedy Jr. ordered a new FDA review of mifepristone’s safety and cited a self‑published white paper funded by anti‑abortion groups as the basis.
  • Americans United for Life and allied groups criticized FDA’s approval of a new generic mifepristone and helped produce/publicize the white paper.
  • Alliance Defending Freedom says it represents a Louisiana plaintiff in a medication‑abortion case against FDA and expects the administration to appeal the recent court order.
  • The ACLU’s Nov. 13 FOIA lawsuit seeks the parameters of FDA’s new review and the agency’s communications with outside groups about it.